GSK has rejected Unilever’s £50bn bid for the former’s Consumer Healthcare business. The British UK giant believes that the offer significantly undervalues its assets, but the acquirer increasing its offer won’t be an easy affair. Nevertheless, this offer is a validation of the underlying potential of consumer health offerings and, hence, we upgrade our divisional NAV estimates. Overall, GSK remains an attractive under-transition pharma story.
17 Jan 2022
Unilever’s bid adds zing to Consumer Healthcare
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Unilever’s bid adds zing to Consumer Healthcare
GSK plc (GSK:LON) | 1,589 -325.7 (-1.3%) | Mkt Cap: 65,862m
- Published:
17 Jan 2022 -
Author:
Amandeep Goyal -
Pages:
3
GSK has rejected Unilever’s £50bn bid for the former’s Consumer Healthcare business. The British UK giant believes that the offer significantly undervalues its assets, but the acquirer increasing its offer won’t be an easy affair. Nevertheless, this offer is a validation of the underlying potential of consumer health offerings and, hence, we upgrade our divisional NAV estimates. Overall, GSK remains an attractive under-transition pharma story.